Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer

다국어 초록 (Multilingual Abstract)

Cer vical cancer continues to be a global threat affecting individuals in resource poorcommunities disproportionately. The treatment paradigm for this disease is ever evolvingwith recent innovations propelling oncologic outcomes to a new frontier offering sur vivalbenefits for patients struggling with locally advanced disease and metastatic/recurrentcarcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent twonovel drug classes that have demonstrable activity in this disease, particularly in the first-lineand second-line treatment paradigm for recurrence. The tolerability of these novel medicinesand associated durable responses underscore regulator y approval by the U.S. Food and DrugAdministrations and their implementation in clinic.